OLATHE, Kan.--(BUSINESS WIRE)--Metactive Medical Inc. (Metactive), an early-stage company focused on developing embolization devices for the treatment of peripheral vascular and neurovascular diseases, today announced that it has closed on $2 million of additional Series A financing, led by the Kansas Bioscience Authority (KBA), an existing Metactive investor. Proceeds will be used to continue the development of Metactive’s novel embolic devices for occlusion of saccular aneurysms and peripheral arteries and veins. Metactive previously raised $5 million in Series A funding, bringing the total funding raised to date to $7 million.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
